Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 282

1.

Sparse force-bearing bridges between neighboring synaptic vesicles.

Wesseling JF, Phan S, Bushong EA, Siksou L, Marty S, Pérez-Otaño I, Ellisman M.

Brain Struct Funct. 2019 Oct 30. doi: 10.1007/s00429-019-01966-x. [Epub ahead of print]

PMID:
31667576
2.

Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?

van der Velden BHM, Bismeijer T, Canisius S, Loo CE, Lips EH, Wesseling J, Viergever MA, Wessels LFA, Gilhuijs KGA.

Eur J Radiol. 2019 Oct 16;121:108705. doi: 10.1016/j.ejrad.2019.108705. [Epub ahead of print]

3.

Response to Preoperative Radiation Therapy in Relation to Gene Expression Patterns in Breast Cancer Patients.

Bosma SCJ, Hoogstraat M, van der Leij F, de Maaker M, Wesseling J, Lips E, Loo CE, Rutgers EJ, Elkhuizen PHM, Bartelink H, van de Vijver MJ.

Int J Radiat Oncol Biol Phys. 2019 Sep 13. pii: S0360-3016(19)33756-3. doi: 10.1016/j.ijrobp.2019.09.002. [Epub ahead of print]

PMID:
31525407
4.

Proteomic profiling of extracellular vesicles allows for human breast cancer subtyping.

Rontogianni S, Synadaki E, Li B, Liefaard MC, Lips EH, Wesseling J, Wu W, Altelaar M.

Commun Biol. 2019 Sep 3;2:325. doi: 10.1038/s42003-019-0570-8. eCollection 2019.

5.

Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study.

Mannu GS, Groen EJ, Wang Z, Schaapveld M, Lips EH, Chung M, Joore I, van Leeuwen FE, Teertstra HJ, Winter-Warnars GAO, Darby SC, Wesseling J.

Breast Cancer Res Treat. 2019 Nov;178(2):409-418. doi: 10.1007/s10549-019-05362-1. Epub 2019 Aug 6.

6.

Toward a Unified Terminology of Processing Levels for Low-Cost Air-Quality Sensors.

Schneider P, Bartonova A, Castell N, Dauge FR, Gerboles M, Hagler GSW, Hüglin C, Jones RL, Khan S, Lewis AC, Mijling B, Müller M, Penza M, Spinelle L, Stacey B, Vogt M, Wesseling J, Williams RW.

Environ Sci Technol. 2019 Aug 6;53(15):8485-8487. doi: 10.1021/acs.est.9b03950. Epub 2019 Jul 29. No abstract available.

PMID:
31353903
7.

Avoiding Overtreatment of Ductal Carcinoma in situ.

van der Borden CL, Stoffers S, Lips EH, Wesseling J.

Trends Cancer. 2019 Jul;5(7):391-393. doi: 10.1016/j.trecan.2019.05.005. Epub 2019 Jun 20.

PMID:
31311652
8.

Ductal carcinoma in situ: to treat or not to treat, that is the question.

van Seijen M, Lips EH, Thompson AM, Nik-Zainal S, Futreal A, Hwang ES, Verschuur E, Lane J, Jonkers J, Rea DW, Wesseling J; PRECISION team.

Br J Cancer. 2019 Aug;121(4):285-292. doi: 10.1038/s41416-019-0478-6. Epub 2019 Jul 9. Review.

9.

Source apportionment to support air quality planning: Strengths and weaknesses of existing approaches.

Thunis P, Clappier A, Tarrason L, Cuvelier C, Monteiro A, Pisoni E, Wesseling J, Belis CA, Pirovano G, Janssen S, Guerreiro C, Peduzzi E.

Environ Int. 2019 Sep;130:104825. doi: 10.1016/j.envint.2019.05.019. Epub 2019 Jun 18.

10.

Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.

Visser LL, Elshof LE, Van de Vijver K, Groen EJ, Almekinders MM, Sanders J, Bierman C, Peters D, Hofland I, Broeks A, van Leeuwen FE, Rutgers EJT, Schmidt MK, Schaapveld M, Lips EH, Wesseling J.

Am J Surg Pathol. 2019 Nov;43(11):1574-1582. doi: 10.1097/PAS.0000000000001306.

PMID:
31206365
11.

Utility of diagnostic breast excision biopsies during two decades of screening mammography.

Luiten JD, Voogd AC, Tjan-Heijnen VCG, Wesseling J, Luiten EJT, Duijm LEM.

Breast. 2019 Aug;46:157-162. doi: 10.1016/j.breast.2019.05.018. Epub 2019 Jun 1.

PMID:
31195315
12.

Elevated synaptic vesicle release probability in synaptophysin/gyrin family quadruple knockouts.

Raja MK, Preobraschenski J, Del Olmo-Cabrera S, Martinez-Turrillas R, Jahn R, Perez-Otano I, Wesseling JF.

Elife. 2019 May 15;8. pii: e40744. doi: 10.7554/eLife.40744.

13.

Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.

Steenbruggen TG, van Seijen M, Janssen LM, van Ramshorst MS, van Werkhoven E, Vrancken Peeters MTDF, Wesseling J, Lips EH, Sonke GS.

Clin Cancer Res. 2019 Aug 15;25(16):4985-4992. doi: 10.1158/1078-0432.CCR-19-0560. Epub 2019 May 10.

PMID:
31076546
14.

EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.

Puppe J, Opdam M, Schouten PC, Jóźwiak K, Lips E, Severson T, van de Ven M, Brambillasca C, Bouwman P, van Tellingen O, Bernards R, Wesseling J, Eichler C, Thangarajah F, Malter W, Pandey GK, Ozretić L, Caldas C, van Lohuizen M, Hauptmann M, Rhiem K, Hahnen E, Reinhardt HC, Büttner R, Mallmann P, Schömig-Markiefka B, Schmutzler R, Linn S, Jonkers J.

Clin Cancer Res. 2019 Jul 15;25(14):4351-4362. doi: 10.1158/1078-0432.CCR-18-4024. Epub 2019 Apr 29.

PMID:
31036541
15.

Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses.

Visser LL, Groen EJ, van Leeuwen FE, Lips EH, Schmidt MK, Wesseling J.

Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):835-845. doi: 10.1158/1055-9965.EPI-18-0976. Epub 2019 Apr 25. Review.

PMID:
31023696
16.

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.

Szijgyarto Z, Flach KD, Opdam M, Palmieri C, Linn SC, Wesseling J, Ali S, Bliss JM, Cheang MCU, Zwart W, Coombes RC.

Breast Cancer Res Treat. 2019 May;175(1):149-163. doi: 10.1007/s10549-018-05110-x. Epub 2019 Jan 24.

17.

Prevalence and development of hip and knee osteoarthritis according to American College of Rheumatology criteria in the CHECK cohort.

Damen J, van Rijn RM, Emans PJ, Hilberdink WKHA, Wesseling J, Oei EHG, Bierma-Zeinstra SMA.

Arthritis Res Ther. 2019 Jan 5;21(1):4. doi: 10.1186/s13075-018-1785-7.

18.

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.

van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG).

Lancet Oncol. 2018 Dec;19(12):1630-1640. doi: 10.1016/S1470-2045(18)30570-9. Epub 2018 Nov 6.

PMID:
30413379
19.

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).

van Rossum AGJ, Kok M, van Werkhoven E, Opdam M, Mandjes IAM, van Leeuwen-Stok AE, van Tinteren H, Imholz ALT, Portielje JEA, Bos MMEM, van Bochove A, Wesseling J, Rutgers EJ, Linn SC, Oosterkamp HM; MATADOR Trialists' Group.

Eur J Cancer. 2018 Oct;102:40-48. doi: 10.1016/j.ejca.2018.07.013.

20.

Breast cancer-related deaths according to grade in ductal carcinoma in situ: A Dutch population-based study on patients diagnosed between 1999 and 2012.

van Maaren MC, Lagendijk M, Tilanus-Linthorst MMA, de Munck L, Pijnappel RM, Schmidt MK, Wesseling J, Koppert LB, Siesling S.

Eur J Cancer. 2018 Sep;101:134-142. doi: 10.1016/j.ejca.2018.07.003. Epub 2018 Jul 28.

PMID:
30059817
21.

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot.

Beelen K, Opdam M, Severson T, Koornstra R, Vincent A, Wesseling J, Sanders J, Vermorken J, van Diest P, Linn S.

BMC Cancer. 2018 Jul 24;18(1):761. doi: 10.1186/s12885-018-4516-1.

22.

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.

Schrijver W, Schuurman K, van Rossum A, Droog M, Jeronimo C, Salta S, Henrique R, Wesseling J, Moelans C, Linn SC, van den Heuvel M, van Diest P, Zwart W.

Mol Oncol. 2018 Nov;12(11):1884-1894. doi: 10.1002/1878-0261.12353. Epub 2018 Oct 12.

23.

Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial.

Heitink-Pollé KMJ, Uiterwaal CSPM, Porcelijn L, Tamminga RYJ, Smiers FJ, van Woerden NL, Wesseling J, Vidarsson G, Laarhoven AG, de Haas M, Bruin MCA; TIKI Investigators.

Blood. 2018 Aug 30;132(9):883-891. doi: 10.1182/blood-2018-02-830844. Epub 2018 Jun 26.

PMID:
29945954
24.

Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study.

van Steenhoven JEC, Kuijer A, van Diest PJ, van Gorp JM, Straver M, Elias SG, Wesseling J, Rutgers E, Timmer-Bonte JNH, Nieboer P, Smilde TJ, Imholz A, Blanken CFJM, Siesling S, van Dalen T.

Genes (Basel). 2018 May 17;9(5). pii: E261. doi: 10.3390/genes9050261.

25.

Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ-A Nested Case-Control Study.

Visser LL, Elshof LE, Schaapveld M, van de Vijver K, Groen EJ, Almekinders MM, Bierman C, van Leeuwen FE, Rutgers EJ, Schmidt MK, Lips EH, Wesseling J.

Clin Cancer Res. 2018 Aug 1;24(15):3593-3601. doi: 10.1158/1078-0432.CCR-18-0201. Epub 2018 Apr 23.

26.

The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors.

Bronsveld HK, De Bruin ML, Wesseling J, Sanders J, Hofland I, Jensen V, Bazelier MT, Ter Braak B, de Boer A, Vestergaard P, Schmidt MK.

BMC Cancer. 2018 Feb 27;18(1):224. doi: 10.1186/s12885-018-4072-8.

27.

Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients.

Sobral-Leite M, Lips EH, Vieira-Monteiro HA, Giacomin LC, Freitas-Alves DR, Cornelissen S, Mulder L, Wesseling J, Schmidt MK, Vianna-Jorge R.

PLoS One. 2017 Dec 21;12(12):e0189750. doi: 10.1371/journal.pone.0189750. eCollection 2017.

28.

Enrichment of high-grade tumors in breast cancer gene expression studies.

van Seijen M, Mooyaart AL, Mulder L, Hoogstraat M, Drukker CA, Loo CE, Pouw B, Sonke GS, Wesseling J, Lips EH.

Breast Cancer Res Treat. 2018 Apr;168(2):327-335. doi: 10.1007/s10549-017-4622-9. Epub 2017 Dec 18.

29.

Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study.

Dackus GM, Ter Hoeve ND, Opdam M, Vreuls W, Varga Z, Koop E, Willems SM, Van Deurzen CH, Groen EJ, Cordoba A, Bart J, Mooyaart AL, van den Tweel JG, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Amant F, Broeks A, Kerkhoven R, Stathonikos N, Veta M, Voogd A, Jozwiak K, Hauptmann M, Hoogstraat M, Schmidt MK, Sonke G, van der Wall E, Siesling S, van Diest PJ, Linn SC.

BMJ Open. 2017 Nov 14;7(11):e017842. doi: 10.1136/bmjopen-2017-017842.

30.

Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.

Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Dennis J, Jiang X, Rostamianfar A, Finucane H, Bolla MK, McGuffog L, Wang Q, Aalfs CM; ABCTB Investigators, Adams M, Adlard J, Agata S, Ahmed S, Ahsan H, Aittomäki K, Al-Ejeh F, Allen J, Ambrosone CB, Amos CI, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Auber B, Auer PL, Ausems MGEM, Azzollini J, Bacot F, Balmaña J, Barile M, Barjhoux L, Barkardottir RB, Barrdahl M, Barnes D, Barrowdale D, Baynes C, Beckmann MW, Benitez J, Bermisheva M, Bernstein L, Bignon YJ, Blazer KR, Blok MJ, Blomqvist C, Blot W, Bobolis K, Boeckx B, Bogdanova NV, Bojesen A, Bojesen SE, Bonanni B, Børresen-Dale AL, Bozsik A, Bradbury AR, Brand JS, Brauch H, Brenner H, Bressac-de Paillerets B, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Brunet J, Brüning T, Burwinkel B, Buys SS, Byun J, Cai Q, Caldés T, Caligo MA, Campbell I, Canzian F, Caron O, Carracedo A, Carter BD, Castelao JE, Castera L, Caux-Moncoutier V, Chan SB, Chang-Claude J, Chanock SJ, Chen X, Cheng TD, Chiquette J, Christiansen H, Claes KBM, Clarke CL, Conner T, Conroy DM, Cook J, Cordina-Duverger E, Cornelissen S, Coupier I, Cox A, Cox DG, Cross SS, Cuk K, Cunningham JM, Czene K, Daly MB, Damiola F, Darabi H, Davidson R, De Leeneer K, Devilee P, Dicks E, Diez O, Ding YC, Ditsch N, Doheny KF, Domchek SM, Dorfling CM, Dörk T, Dos-Santos-Silva I, Dubois S, Dugué PA, Dumont M, Dunning AM, Durcan L, Dwek M, Dworniczak B, Eccles D, Eeles R, Ehrencrona H, Eilber U, Ejlertsen B, Ekici AB, Eliassen AH; EMBRACE, Engel C, Eriksson M, Fachal L, Faivre L, Fasching PA, Faust U, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Foulkes WD, Friedman E, Fritschi L, Frost D, Gabrielson M, Gaddam P, Gammon MD, Ganz PA, Gapstur SM, Garber J, Garcia-Barberan V, García-Sáenz JA, Gaudet MM, Gauthier-Villars M, Gehrig A; GEMO Study Collaborators, Georgoulias V, Gerdes AM, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Goodfellow P, Greene MH, Alnæs GIG, Grip M, Gronwald J, Grundy A, Gschwantler-Kaulich D, Guénel P, Guo Q, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hallberg E, Hamann U, Hamel N, Hankinson S, Hansen TVO, Harrington P, Hart SN, Hartikainen JM, Healey CS; HEBON, Hein A, Helbig S, Henderson A, Heyworth J, Hicks B, Hillemanns P, Hodgson S, Hogervorst FB, Hollestelle A, Hooning MJ, Hoover B, Hopper JL, Hu C, Huang G, Hulick PJ, Humphreys K, Hunter DJ, Imyanitov EN, Isaacs C, Iwasaki M, Izatt L, Jakubowska A, James P, Janavicius R, Janni W, Jensen UB, John EM, Johnson N, Jones K, Jones M, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kaczmarek K, Kang D, Kast K; kConFab/AOCS Investigators, Keeman R, Kerin MJ, Kets CM, Keupers M, Khan S, Khusnutdinova E, Kiiski JI, Kim SW, Knight JA, Konstantopoulou I, Kosma VM, Kristensen VN, Kruse TA, Kwong A, Lænkholm AV, Laitman Y, Lalloo F, Lambrechts D, Landsman K, Lasset C, Lazaro C, Le Marchand L, Lecarpentier J, Lee A, Lee E, Lee JW, Lee MH, Lejbkowicz F, Lesueur F, Li J, Lilyquist J, Lincoln A, Lindblom A, Lissowska J, Lo WY, Loibl S, Long J, Loud JT, Lubinski J, Luccarini C, Lush M, MacInnis RJ, Maishman T, Makalic E, Kostovska IM, Malone KE, Manoukian S, Manson JE, Margolin S, Martens JWM, Martinez ME, Matsuo K, Mavroudis D, Mazoyer S, McLean C, Meijers-Heijboer H, Menéndez P, Meyer J, Miao H, Miller A, Miller N, Mitchell G, Montagna M, Muir K, Mulligan AM, Mulot C, Nadesan S, Nathanson KL; NBSC Collaborators, Neuhausen SL, Nevanlinna H, Nevelsteen I, Niederacher D, Nielsen SF, Nordestgaard BG, Norman A, Nussbaum RL, Olah E, Olopade OI, Olson JE, Olswold C, Ong KR, Oosterwijk JC, Orr N, Osorio A, Pankratz VS, Papi L, Park-Simon TW, Paulsson-Karlsson Y, Lloyd R, Pedersen IS, Peissel B, Peixoto A, Perez JIA, Peterlongo P, Peto J, Pfeiler G, Phelan CM, Pinchev M, Plaseska-Karanfilska D, Poppe B, Porteous ME, Prentice R, Presneau N, Prokofieva D, Pugh E, Pujana MA, Pylkäs K, Rack B, Radice P, Rahman N, Rantala J, Rappaport-Fuerhauser C, Rennert G, Rennert HS, Rhenius V, Rhiem K, Richardson A, Rodriguez GC, Romero A, Romm J, Rookus MA, Rudolph A, Ruediger T, Saloustros E, Sanders J, Sandler DP, Sangrajrang S, Sawyer EJ, Schmidt DF, Schoemaker MJ, Schumacher F, Schürmann P, Schwentner L, Scott C, Scott RJ, Seal S, Senter L, Seynaeve C, Shah M, Sharma P, Shen CY, Sheng X, Shimelis H, Shrubsole MJ, Shu XO, Side LE, Singer CF, Sohn C, Southey MC, Spinelli JJ, Spurdle AB, Stegmaier C, Stoppa-Lyonnet D, Sukiennicki G, Surowy H, Sutter C, Swerdlow A, Szabo CI, Tamimi RM, Tan YY, Taylor JA, Tejada MI, Tengström M, Teo SH, Terry MB, Tessier DC, Teulé A, Thöne K, Thull DL, Tibiletti MG, Tihomirova L, Tischkowitz M, Toland AE, Tollenaar RAEM, Tomlinson I, Tong L, Torres D, Tranchant M, Truong T, Tucker K, Tung N, Tyrer J, Ulmer HU, Vachon C, van Asperen CJ, Van Den Berg D, van den Ouweland AMW, van Rensburg EJ, Varesco L, Varon-Mateeva R, Vega A, Viel A, Vijai J, Vincent D, Vollenweider J, Walker L, Wang Z, Wang-Gohrke S, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wesseling J, Whittemore AS, Wijnen JT, Willett W, Winqvist R, Wolk A, Wu AH, Xia L, Yang XR, Yannoukakos D, Zaffaroni D, Zheng W, Zhu B, Ziogas A, Ziv E, Zorn KK, Gago-Dominguez M, Mannermaa A, Olsson H, Teixeira MR, Stone J, Offit K, Ottini L, Park SK, Thomassen M, Hall P, Meindl A, Schmutzler RK, Droit A, Bader GD, Pharoah PDP, Couch FJ, Easton DF, Kraft P, Chenevix-Trench G, García-Closas M, Schmidt MK, Antoniou AC, Simard J.

Nat Genet. 2017 Dec;49(12):1767-1778. doi: 10.1038/ng.3785. Epub 2017 Oct 23.

31.

Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study.

Kuijer A, Straver M, den Dekker B, van Bommel ACM, Elias SG, Smorenburg CH, Wesseling J, Linn SC, Rutgers EJT, Siesling S, van Dalen T.

J Clin Oncol. 2017 Aug 20;35(24):2814-2819. doi: 10.1200/JCO.2016.70.3959. Epub 2017 Mar 13.

PMID:
28813638
32.

Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials.

Grimm LJ, Ryser MD, Partridge AH, Thompson AM, Thomas JS, Wesseling J, Hwang ES.

Ann Surg Oncol. 2017 Nov;24(12):3534-3540. doi: 10.1245/s10434-017-6018-9. Epub 2017 Aug 9.

33.

The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study.

Roeke T, Sobral-Leite M, Dekker TJA, Wesseling J, Smit VTHBM, Tollenaar RAEM, Schmidt MK, Mesker WE.

Breast Cancer Res Treat. 2017 Nov;166(2):435-445. doi: 10.1007/s10549-017-4445-8. Epub 2017 Aug 9.

PMID:
28795248
34.

Response to: "DCIS and Breast Cancer: Challenging the Paradigm".

Schaapveld M, Wesseling J.

Ann Surg. 2018 Jul;268(1):e18. doi: 10.1097/SLA.0000000000002418. No abstract available.

PMID:
28697052
35.

Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.

Kas SM, de Ruiter JR, Schipper K, Annunziato S, Schut E, Klarenbeek S, Drenth AP, van der Burg E, Klijn C, Ten Hoeve JJ, Adams DJ, Koudijs MJ, Wesseling J, Nethe M, Wessels LFA, Jonkers J.

Nat Genet. 2017 Aug;49(8):1219-1230. doi: 10.1038/ng.3905. Epub 2017 Jun 26.

PMID:
28650484
36.

Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer.

van Ramshorst MS, Teixeira SC, Koolen BB, Pengel KE, Gilhuijs KG, Wesseling J, Rodenhuis S, Valdés Olmos RA, Rutgers EJ, Vogel WV, Sonke GS, Vrancken Peeters MT.

Cancer Imaging. 2017 May 25;17(1):15. doi: 10.1186/s40644-017-0117-5.

37.

Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes.

Schmitz AMT, Teixeira SC, Pengel KE, Loo CE, Vogel WV, Wesseling J, Rutgers EJT, Valdés Olmos RA, Sonke GS, Rodenhuis S, Vrancken Peeters MJTFD, Gilhuijs KGA.

PLoS One. 2017 May 22;12(5):e0176782. doi: 10.1371/journal.pone.0176782. eCollection 2017.

38.

MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy.

van Ramshorst MS, Loo CE, Groen EJ, Winter-Warnars GH, Wesseling J, van Duijnhoven F, Peeters MTV, Sonke GS.

Breast Cancer Res Treat. 2017 Jul;164(1):99-106. doi: 10.1007/s10549-017-4254-0. Epub 2017 Apr 21.

PMID:
28432515
39.

Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.

Schmidt MK, van den Broek AJ, Tollenaar RA, Smit VT, Westenend PJ, Brinkhuis M, Oosterhuis WJ, Wesseling J, Janssen-Heijnen ML, Jobsen JJ, Jager A, Voogd AC, van Leeuwen FE, van 't Veer LJ.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw329.

PMID:
28376189
40.

Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ.

Elshof LE, Schmidt MK, Rutgers EJT, van Leeuwen FE, Wesseling J, Schaapveld M.

Ann Surg. 2018 May;267(5):952-958. doi: 10.1097/SLA.0000000000002239.

41.

Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.

van Ramshorst MS, van Werkhoven E, Mandjes IAM, Schot M, Wesseling J, Vrancken Peeters MTFD, Meerum Terwogt JM, Bos MEM, Oosterkamp HM, Rodenhuis S, Linn SC, Sonke GS.

Eur J Cancer. 2017 Mar;74:47-54. doi: 10.1016/j.ejca.2016.12.023. Epub 2017 Feb 10.

PMID:
28335887
42.

Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review.

Lindenberg MA, Miquel-Cases A, Retèl VP, Sonke GS, Wesseling J, Stokkel MPM, van Harten WH.

Crit Rev Oncol Hematol. 2017 Apr;112:198-207. doi: 10.1016/j.critrevonc.2017.02.014. Epub 2017 Feb 17. Review.

PMID:
28325260
43.

The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.

Elshof LE, Schaapveld M, Rutgers EJ, Schmidt MK, de Munck L, van Leeuwen FE, Wesseling J.

Breast Cancer Res. 2017 Mar 9;19(1):26. doi: 10.1186/s13058-017-0819-4.

44.

Predictive value of MRI features for development of radiographic osteoarthritis in a cohort of participants with pre-radiographic knee osteoarthritis-the CHECK study.

van Oudenaarde K, Jobke B, Oostveen AC, Marijnissen AC, Wolterbeek R, Wesseling J, Bierma-Zeinstra SM, Bloem HL, Reijnierse M, Kloppenburg M.

Rheumatology (Oxford). 2017 Jan;56(1):113-120. doi: 10.1093/rheumatology/kew368. Epub 2016 Oct 25.

PMID:
28028160
45.

Erratum to: Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.

Elshof LE, Schaapveld M, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J.

Breast Cancer Res Treat. 2017 Jan;161(2):389-390. doi: 10.1007/s10549-016-4060-0. No abstract available.

PMID:
27878644
46.

Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.

Abubakar M, Orr N, Daley F, Coulson P, Ali HR, Blows F, Benitez J, Milne R, Brenner H, Stegmaier C, Mannermaa A, Chang-Claude J, Rudolph A, Sinn P, Couch FJ, Devilee P, Tollenaar RA, Seynaeve C, Figueroa J, Sherman ME, Lissowska J, Hewitt S, Eccles D, Hooning MJ, Hollestelle A, Martens JW, van Deurzen CH, Investigators K, Bolla MK, Wang Q, Jones M, Schoemaker M, Wesseling J, van Leeuwen FE, Van 't Veer L, Easton D, Swerdlow AJ, Dowsett M, Pharoah PD, Schmidt MK, Garcia-Closas M.

Breast Cancer Res. 2016 Oct 18;18(1):104.

47.

Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).

Groen EJ, Elshof LE, Visser LL, Rutgers EJT, Winter-Warnars HAO, Lips EH, Wesseling J.

Breast. 2017 Feb;31:274-283. doi: 10.1016/j.breast.2016.09.001. Epub 2016 Sep 23. Review.

PMID:
27671693
48.

Changes in peripheral blood lymphocyte subsets during arthritis development in arthralgia patients.

Lübbers J, van Beers-Tas MH, Vosslamber S, Turk SA, de Ridder S, Mantel E, Wesseling JG, Reijm M, van Hoogstraten IM, Bijlsma JW, van Schaardenburg D, Bontkes HJ, Verweij CL.

Arthritis Res Ther. 2016 Sep 14;18(1):205. doi: 10.1186/s13075-016-1102-2.

49.

Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.

Elshof LE, Schaapveld M, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J.

Breast Cancer Res Treat. 2016 Oct;159(3):553-63. doi: 10.1007/s10549-016-3973-y. Epub 2016 Sep 8. Erratum in: Breast Cancer Res Treat. 2017 Jan;161(2):389-390.

50.

BRCA1-Mutated Estrogen Receptor-Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency.

Lips EH, Debipersad RD, Scheerman CE, Mulder L, Sonke GS, van der Kolk LE, Wesseling J, Hogervorst FB, Nederlof PM.

Clin Cancer Res. 2017 Mar 1;23(5):1236-1241. doi: 10.1158/1078-0432.CCR-16-0198. Epub 2016 Sep 12.

Supplemental Content

Loading ...
Support Center